ArticleFrontiers in pediatrics2022

Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial).

Dariusz Madajczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.